Evidence map›Paper›PMID 30519730›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2019

Institutional patient accrual volume and the treatment quality of I‑125 prostate seed implantation in a Japanese nationwide prospective cohort study.

Katsumasa Nakamura, Saiji Ohga, Atsunori Yorozu, Shiro Saito, Takashi Kikuchi, Takushi Dokiya, Masanori Fukushima, Hidetoshi Yamanaka

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Article
  2. Article
  3. Current status of prostate brachytherapy in Japan.Japanese journal of radiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katsumasa NakamuraDepartment of Radiation Oncology, Hamamatsu University School of Medicine, Handayama 1‑20-1, Higashi-ku, 431-3192, Hamamatsu, Japan. nakam@hama-med.ac.jp.ORCID http://orcid.org/0000-0003-2090-881X
Saiji OhgaDepartment of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Atsunori YorozuDepartment of Radiology, National HospitalOrganization Tokyo Medical Center, Tokyo, Japan.
Shiro SaitoDepartment of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Takashi KikuchiTranslational Research Center for Medical Innovation, Hyogo, Japan.
Takushi DokiyaDepartment of Radiology, Sasaki Foundation Kyoundo Hospital, Tokyo, Japan.
Masanori FukushimaTranslational Research Center for Medical Innovation, Hyogo, Japan.
Hidetoshi YamanakaJapanese Foundation for Prostate Research, Tokyo, Japan.

Funding

Health Labor Sciences Research Grant (Japan) H29-ICT-Ippan-002
6 · The paper itself

Abstract

purposeIt is unclear whether experience at high-volume institute improves the treatment quality of prostate seed implantation. The aim of this study was to evaluate the effect of institutional experience on postimplant dosimetric parameters in a nationwide prospective cohort study.

methodsFrom July 2005 to June 2007, 2354 patients were registered in the Japanese Prostate Cancer Outcome Study of Permanent I‑125 Seed Implantation (J-POPS), and 1126 patients treated with seed implantation alone were evaluated. As a surrogate for institutional experience, we classified the J‑POPS institutions as high-volume (patient accrual volume was ≥120 patients per institution) or low-volume institutions (patient accrual volume was <120 patients per institution). To compare treatment quality between institutions, we evaluated the postimplant dosimetric parameters including D90, V100/150 (prostatic dose parameters), UD5/90, U200 (urethral dose parameters), and rectum R100/150 (rectal dose parameters).

resultsIn the 5 high-volume institutions (n = 601 patients), most of the patients were treated with >144 Gy of D90, whereas in the 20 low-volume institutions (n = 525) some of the patients were treated with <144 Gy. The V100 of most of the high-volume institution patients were >90%, whereas in the low-volume institutions a considerable percentage of patients showed lower V100. Although there was no correlation between D90 and rectal dose parameters, UD90 had a moderate positive correlation with D90 in both the high- and low-volume institutions. U200 varied more widely in the low-volume institutions.

conclusionsOur findings indicate that the institutional patient accrual volume is associated with the treatment quality of I‑125 prostate seed implantation.

Indexed as

Treatment OutcomeBrachytherapyClinical CompetenceCohort StudiesHospitals, High-VolumeHumansIodine RadioisotopesMaleOrgans at RiskProspective StudiesQuality Assurance, Health CareRadiometryRectumUrethraIodine RadioisotopesBrachytherapyDose-volume histogramInstitutional experienceProstate cancerTreatment quality

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.